Phytochemical and Pharmacological Investigation of Hydroalcoholic Leaf Extracts of Hamelia patens Jacq. and Ixora coccinea Linn. for Antidepressant Activity in Experimental Animal Models

Depression is a common and debilitating neuropsychiatric disorder characterized by persistent sadness, loss of interest, behavioral changes, and disturbances in emotional and cognitive functions. Although several synthetic antidepressant drugs are available for the management of depression, their therapeutic limitations and adverse effects have stimulated the search for safer and effective plant-based alternatives. The present study was designed to investigate the phytochemical profile and antidepressant potential of hydroalcoholic leaf extracts of Hamelia patens Jacq. and Ixora coccinea Linn. using experimental animal models.
The leaves of Hamelia patens and Ixora coccinea were collected, authenticated, shade-dried, powdered, and subjected to extraction using a hydroalcoholic solvent system. The prepared extracts were evaluated for preliminary phytochemical constituents, including alkaloids, flavonoids, phenolic compounds, tannins, saponins, glycosides, terpenoids, steroids, and other secondary metabolites. The antidepressant activity of the extracts was evaluated in suitable experimental animal models, particularly the Forced Swim Test (FST) and Tail Suspension Test (TST). An Open Field Test (OFT) was additionally employed to assess locomotor activity and to differentiate antidepressant-like effects from nonspecific motor stimulation. A standard antidepressant drug was used as the positive control.
The hydroalcoholic leaf extracts demonstrated the presence of several biologically important phytoconstituents, particularly flavonoids, phenolic compounds, alkaloids, tannins, saponins, and terpenoids. Treatment with the extracts produced a dose-dependent reduction in immobility time in the FST and TST compared with the control group, indicating significant antidepressant-like activity. The extracts did not produce marked alterations in locomotor activity in the OFT, suggesting that the observed reduction in immobility was not primarily attributable to nonspecific hyperactivity. The observed activity may be associated with the synergistic action of flavonoids, phenolics, alkaloids, and other bioactive constituents present in the leaves.
The findings of the study suggest that hydroalcoholic leaf extracts of Hamelia patens and Ixora coccinea possess promising antidepressant-like activity in experimental animal models. These medicinal plants may serve as potential sources of bioactive phytoconstituents for the development of novel herbal therapeutic agents for depression. Further studies involving isolation and characterization of active constituents, mechanistic investigations, neurochemical evaluation, and molecular studies are warranted to establish their precise antidepressant mechanism of action.

Hamelia patens, Ixora coccinea, hydroalcoholic extract, phytochemical screening, antidepressant activity, Forced Swim Test, Tail Suspension Test, Open Field Test, medicinal plants.

1. World Health Organization. Depressive disorder (depression). Geneva: World Health Organization; 2025. (World Health Organization) [Google Scholar] [Crossref]

2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text Revision (DSM-5-TR). Washington (DC): American Psychiatric Association; 2022. [Google Scholar] [Crossref]

3. Marx W, Penninx BWJH, Solmi M, Furukawa TA, Firth J, Carvalho AF, et al. Major depressive disorder. Nat Rev Dis Primers. 2023;9:44. (Nature) [Google Scholar] [Crossref]

4. Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023. [Google Scholar] [Crossref]

5. Katzung BG, Vanderah TW. Basic and Clinical Pharmacology. 16th ed. New York: McGraw-Hill Education; 2024. [Google Scholar] [Crossref]

6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 10th ed. London: Elsevier; 2024. [Google Scholar] [Crossref]

7. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021. [Google Scholar] [Crossref]

8. Tripathi KD. Essentials of Medical Pharmacology. 9th ed. New Delhi: Jaypee Brothers Medical Publishers; 2024. [Google Scholar] [Crossref]

9. Harborne JB. Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis. 3rd ed. London: Chapman & Hall; 1998. [Google Scholar] [Crossref]

10. Evans WC. Trease and Evans Pharmacognosy. 16th ed. London: Saunders Elsevier; 2009. [Google Scholar] [Crossref]

11. Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. 58th ed. Pune: Nirali Prakashan; 2023. [Google Scholar] [Crossref]

12. Dewick PM. Medicinal Natural Products: A Biosynthetic Approach. 3rd ed. Chichester: John Wiley & Sons; 2009. [Google Scholar] [Crossref]

13. Heinrich M, Barnes J, Gibbons S, Williamson EM. Fundamentals of Pharmacognosy and Phytotherapy. 3rd ed. London: Elsevier; 2018. [Google Scholar] [Crossref]

14. Organisation for Economic Co-operation and Development. OECD Guideline for the Testing of Chemicals No. 423: Acute Oral Toxicity – Acute Toxic Class Method. Paris: OECD Publishing; 2002. [Google Scholar] [Crossref]

15. Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). Guidelines for Laboratory Animal Facility. New Delhi: Government of India; 2003. [Google Scholar] [Crossref]

16. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines. PLoS Biol. 2010;8(6):e1000412. [Google Scholar] [Crossref]

17. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977;266(5604):730–732. [Google Scholar] [Crossref]

18. Porsolt RD, Bertin A, Jalfre M. Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977;229(2):327–336. [Google Scholar] [Crossref]

19. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985;85(3):367–370. [Google Scholar] [Crossref]

20. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci. 2002;23(5):238–245. [Google Scholar] [Crossref]

21. Cryan JF, Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov. 2005;4(9):775–790. [Google Scholar] [Crossref]

22. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology. 2005;52(2):90–110. [Google Scholar] [Crossref]

23. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68–72. [Google Scholar] [Crossref]

24. Castrén E, Monteggia LM. Brain-derived neurotrophic factor signaling in depression and antidepressant action. Biol Psychiatry. 2021;90(2):128–136. [Google Scholar] [Crossref]

25. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455(7215):894–902. [Google Scholar] [Crossref]

26. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312. [Google Scholar] [Crossref]

27. Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2:16065. [Google Scholar] [Crossref]

28. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358(1):55–68. [Google Scholar] [Crossref]

29. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. 2002;34(1):13–25. [Google Scholar] [Crossref]

30. Miller AH, Raison CL. The role of inflammation in depression. Nat Rev Immunol. 2016;16(1):22–34. [Google Scholar] [Crossref]

31. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new "5-HT" hypothesis of depression: cell-mediated immune activation induces indoleamine-2,3-dioxygenase, leading to lowered plasma tryptophan and increased production of detrimental tryptophan catabolites. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(3):702–721. [Google Scholar] [Crossref]

32. WHO Mental Health Gap Action Programme (mhGAP). Antidepressants (TCAs and SSRIs) in treatment of adults with depression. Geneva: World Health Organization; 2023. (World Health Organization) [Google Scholar] [Crossref]

33. WHO Mental Health Gap Action Programme (mhGAP). Antidepressant medication compared with psychological treatment for moderate-to-severe depressive disorder. Geneva: World Health Organization; 2023. (World Health Organization) [Google Scholar] [Crossref]

34. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol. 2011;21(12):841–860. [Google Scholar] [Crossref]

35. Kumar V. Abbas AK, Aster JC. Robbins & Cotran Pathologic Basis of Disease. 10th ed. Philadelphia: Elsevier; 2020. [Google Scholar] [Crossref]

36. Hall JE. Guyton and Hall Textbook of Medical Physiology. 14th ed. Philadelphia: Elsevier; 2021. [Google Scholar] [Crossref]

37. ICH Harmonised Guideline. M3(R2): Non-clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Geneva: International Council for Harmonisation; 2009. [Google Scholar] [Crossref]

38. Wagner H, Bladt S. Plant Drug Analysis: A Thin Layer Chromatography Atlas. 2nd ed. Berlin: Springer; 1996. [Google Scholar] [Crossref]

39. Sofowora A. Medicinal Plants and Traditional Medicine in Africa. 3rd ed. Ibadan: Spectrum Books Ltd; 2008. [Google Scholar] [Crossref]

40. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect. 2001;109(Suppl 1):69–75. [Google Scholar] [Crossref]

41. Newman DJ, Cragg GM. Natural products as sources of new drugs over nearly four decades from 1981 to 2019. J Nat Prod. 2020;83(3):770–803. [Google Scholar] [Crossref]

42. Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT; International Natural Product Sciences Taskforce. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200–216. [Google Scholar] [Crossref]

43. Calixto JB. Twenty-five years of research on medicinal plants in Latin America: a personal view. J Ethnopharmacol. 2005;100(1-2):131–134. [Google Scholar] [Crossref]

44. Rates SMK. Plants as source of drugs. Toxicon. 2001;39(5):603–613. [Google Scholar] [Crossref]

45. Heinrich M. Ethnopharmacology and drug discovery. In: Iwu MM, Wootton JC, editors. Ethnomedicine and Drug Discovery. Amsterdam: Elsevier; 2002. p. 245–256. [Google Scholar] [Crossref]

46. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005;78(5):431–441. [Google Scholar] [Crossref]

47. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830(6):3670–3695. [Google Scholar] [Crossref]

48. Pan SY, Litscher G, Gao SH, Zhou SF, Yu ZL, Chen HQ, et al. Historical perspective of traditional indigenous medical practices: the current renaissance and conservation of herbal resources. Evid Based Complement Alternat Med. 2014;2014:525340. [Google Scholar] [Crossref]

49. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177. [Google Scholar] [Crossref]

50. Williamson EM, Driver S, Baxter K, editors. Stockley's Herbal Medicines Interactions. 2nd ed. London: Pharmaceutical Press; 2013. [Google Scholar] [Crossref]

51. Duke JA. Handbook of Medicinal Herbs. 2nd ed. Boca Raton: CRC Press; 2002. [Google Scholar] [Crossref]

52. Evans WC. Trease and Evans' Pharmacognosy. 15th ed. London: WB Saunders; 2002. [Google Scholar] [Crossref]

53. Farnsworth NR. Biological and phytochemical screening of plants. J Pharm Sci. 1966;55(3):225–276. [Google Scholar] [Crossref]

54. Cos P, Vlietinck AJ, Berghe DV, Maes L. Anti-infective potential of natural products: how to develop a stronger in vitro proof-of-concept. J Ethnopharmacol. 2006;106(3):290–302. [Google Scholar] [Crossref]

55. Sofowora A, Ogunbodede E, Onayade A. The role and place of medicinal plants in the strategies for disease prevention. Afr J Tradit Complement Altern Med. 2013;10(5):210–229. [Google Scholar] [Crossref]

56. Edeoga HO, Okwu DE, Mbaebie BO. Phytochemical constituents of some Nigerian medicinal plants. Afr J Biotechnol. 2005;4(7):685–688. [Google Scholar] [Crossref]

57. Harborne JB, Williams CA. Advances in flavonoid research since 1992. Phytochemistry. 2000;55(6):481–504. [Google Scholar] [Crossref]

58. Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009;2(5):270–278. [Google Scholar] [Crossref]

59. Rice-Evans C, Miller N, Paganga G. Antioxidant properties of phenolic compounds. Trends Plant Sci. 1997;2(4):152–159. [Google Scholar] [Crossref]

60. Heim KE, Tagliaferro AR, Bobilya DJ. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J Nutr Biochem. 2002;13(10):572–584. [Google Scholar] [Crossref]

61. Pietta PG. Flavonoids as antioxidants. J Nat Prod. 2000;63(7):1035–1042. [Google Scholar] [Crossref]

62. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 5th ed. Oxford: Oxford University Press; 2015. [Google Scholar] [Crossref]

63. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84. [Google Scholar] [Crossref]

64. Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180–183. [Google Scholar] [Crossref]

65. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 2009;7(1):65–74. [Google Scholar] [Crossref]

66. Yadav A, Koshti D, Parashar R, Rajoriya V, Sharma Y, Thakur AS. Formulation and evaluation of orodispersible tablets of Galantamine hydrochloride for effective treatment of Alzheimer. Int J Res Innov Appl Sci. 2026;11(3):1539-1561. doi:10.51584/IJRIAS.2026.11030119. [Google Scholar] [Crossref]

67. Athiya, A., koshti, D., Parashar, R., Rajoriya, V., Sharma, Y., Thakur, A. S. (2026). Formulation and Evaluation of Olopatadine Hydrochloride Opthalmic Solution. International Journal of Research and Innovation in Applied Science, 11(6), https://doi.org/10.51584/IJRIAS.2026.11060285. [Google Scholar] [Crossref]

68. Kapil Kumar Tiwari, Ramdarshan Parashar, Pratiksha Jain, Vaibhav Rajoriya, Yogesh Sharma, Ajay Singh Thakur (2026). Standardization, Chemical and Pharmacological Evaluation of Soymida Febrifuga for AntimicrobialandAnti-Inflammatory Activities. , 11(1), [Google Scholar] [Crossref]

69. https://doi.org/10.51584/IJRIAS.2026.110100116. [Google Scholar] [Crossref]

70. Behl C. Oxidative stress in Alzheimer's disease: implications for prevention and therapy. Subcell Biochem. 2005;38:65–78. [Google Scholar] [Crossref]

71. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways contribute to the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 2012;36(2):764–785. [Google Scholar] [Crossref]

72. Berk M, Williams LJ, Jacka FN, O'Neil A, Pasco JA, Moylan S, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200. [Google Scholar] [Crossref]

73. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24–31. [Google Scholar] [Crossref]

74. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732–741. [Google Scholar] [Crossref]

75. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–457. [Google Scholar] [Crossref]

76. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199–229. [Google Scholar] [Crossref]

77. Duman RS. Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci. 2014;16(1):11–27. [Google Scholar] [Crossref]

78. Castrén E. Is mood chemistry? Nat Rev Neurosci. 2005;6(3):241–246. [Google Scholar] [Crossref]

79. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012;64(2):238–258. [Google Scholar] [Crossref]

80. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analysis and implications. Biol Psychiatry. 2008;64(6):527–532. [Google Scholar] [Crossref]

• Artificial Intelligence in Pharmacology, Drug Safety and Toxicity
• Seroprevalence and Associated Risk Factors of Treponema Pallidum Infection among Pregnant Women Attending Antenatal Clinics in Lokoja, Kogi State
• In Silico Evaluation of Hyptis Verticillata-Derived Phytochemicals Targeting Estrogen Receptor Alpha (Erα) and Progesterone Receptor in Hormone-Dependent Breast Cancer
• A Review Article on AI in Personalized Medicine & Novel Pharamacology
• Leech Therapy (Hirudotherapy): A Comprehensive Systematic Review of Pharmacological Constituents, Mechanisms of Action, Therapeutic Applications, and Safety